#USA #Los Angeles #Nordic Pharma #Lacrifill Gel #dry eye therapy

Nordic Pharma Presents Patient Data for Lacrifill® at ASCRS 2025

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is set to present exciting findings at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Los Angeles from April 25-28, 2025. The focus will be on the recent patient data and experience study for Lacrifill® Canalicular Gel, a novel treatment aimed at alleviating symptoms of dry eye.

In the April issue of Cataract & Refractive Surgery Today (CRST), a compelling case study entitled “Improved Visual Outcomes With Lacrifill® Canalicular Gel-Assisted Ocular Surface Optimization” authored by Dr. Neel Desai and Dr. Subhashini Chandrasekaran outlines how the use of Lacrifill can significantly enhance visual acuity in patients who experienced fluctuating vision following cataract surgery.

Dr. Jai Parekh, Chief Commercial Officer of Eye Care U.S., highlighted the impact Lacrifill has made since its launch at last year’s ASCRS. He expressed excitement about presenting proven results to this year’s attendees, emphasizing that the gathered data from a variety of doctors—including both MDs and ODs—demonstrates revolutionary improvements in the treatment of dry eye symptoms.

A noteworthy highlight from the upcoming May issue of CRST illustrates strong patient satisfaction. A survey conducted among both first-time and repeat patients treated with Lacrifill reported that an astounding 98.11% of respondents indicated their willingness to seek further treatment in the future. This affirmation underscores the effectiveness and positive reception of Lacrifill among individuals suffering from dry eye.

Attendees of the ASCRS can visit Nordic Pharma's booth (#717) to experience an engaging presentation from participating medical professionals, including Dr. Priya Mathews from the Center for Sight. Dr. Mathews is eager to share her insights and positive patient outcomes, further elaborating on the advantages of incorporating Lacrifill into practice, referring to the practitioners as 'Lacrifillers.'

In addition to their informative presentations, Nordic Pharma is also committed to supporting the community. In response to recent California wildfires, they are promoting a donation initiative at their booth for the Los Angeles Fire Department Foundation, promising to match a portion of the contributions to amplify their impact on local fire response efforts.

For those interested in learning more or ordering Lacrifill Canalicular Gel, Nordic Pharma invites inquiries via their official website, lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is an international pharmaceutical company poised in the specialty products sector, with recent expansions beyond Europe. Through focused development strategies and acquisitions, it has significantly bolstered its portfolio in various fields, primarily in Eye Care, Rheumatology, and Women’s Health.

About Nordic Pharma, Inc.

As a subsidiary of Nordic Group B.V., Nordic Pharma leverages its partnerships with established global biotech firms, facilitating the introduction of innovative medicines and advanced technologies in the pharmaceutical field.

Safe Harbor Statement

This announcement includes forward-looking statements, reflecting Nordic Group/Nordic Pharma’s outlook regarding future business endeavors, which inherently carry risks and uncertainties. Actual developments may diverge from current expectations due to various market conditions and financial climates. Nordic Group/Nordic Pharma disclaims any intention to update these statements publicly unless legally required to do so.